REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced that the National Health Service England (NHSE) and NHS Improvement have mandated that English hospitals adopt the AI-powered HeartFlow FFRct Analysis to fight coronary heart disease (CHD), the leading cause of death in the UK.
The HeartFlow Analysis has been selected as one of the innovations supported by NHSE’s new MedTech Funding Mandate. The Mandate, which will begin 01 April 2021, aims to provide innovative medical devices and digital products to NHSE patients faster, and is a key policy in helping to improve patient care and reduce costs for the public health service. The Mandate includes the option to extend funding for up to an additional three years through 31 March 2024.
The news comes as HeartFlow announced it also has received extended funding through NHSE’s Innovation and Technology Payment Programme (ITP) for a third year. The programme seeks to accelerate the uptake of innovations in the health service by removing financial…
